Trials / Conditions / Large-cell Lymphoma

Large-cell Lymphoma

12 registered clinical trials studyying Large-cell Lymphoma — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) NCT07443137	Stanford University	Phase 1
Active Not Recruiting	Telehealth-based Symptom Management for Veterans Treated With Selinexor NCT06452446	Durham VA Medical Center	—
Recruiting	Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers NCT05940272	Memorial Sloan Kettering Cancer Center	N/A
Active Not Recruiting	NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell NCT05020678	Nkarta, Inc.	Phase 1
Withdrawn	QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma NCT04052061	ImmunityBio, Inc.	Phase 1
Completed	UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep NCT02722668	Masonic Cancer Center, University of Minnesota	Phase 2
Terminated	Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies NCT02991898	Masonic Cancer Center, University of Minnesota	Phase 2
Completed	Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine NCT02996773	University of Arizona	Phase 1
Completed	Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing NCT02315612	National Cancer Institute (NCI)	Phase 1
Completed	Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma NCT01593696	National Cancer Institute (NCI)	Phase 1
Completed	Safety and Tolerability of HSC835 in Patients With Hematological Malignancies NCT01474681	Novartis Pharmaceuticals	Phase 1 / Phase 2
Completed	Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma NCT00099255	Seagen Inc.	Phase 2